Guidance on Medicaid coverage of preeclampsia screening and detection tests

Title XIX of the Social Security Act (42 U.S.C. 1396 et seq.) is amended by inserting after section 1948 the following new section: 1949. Guidance and technical assistance with respect to coverage of preeclampsia screening and detection tests (a) Guidance Not later than the date that is 180 days after the date of the enactment of this section, the Secretary shall issue guidance to States and, as appropriate, medicaid managed care organizations, on— (1) best practices for improving outcomes for pregnant women with preeclampsia who are eligible for and receiving medical assistance under a State plan (or waiver of such plan) under this title or a State child health plan (or waiver of such plan) under title XXI through early screening, detection, and management; and (2) which tests for the early detection of preeclampsia may be furnished to such pregnant women as medical assistance under such a State plan (or waiver) or such a State child health plan (or waiver), including whether the biomarker tests described in subsection (c) may be so furnished. (b) Technical assistance (1) In general The Secretary shall, not later than 30 days after receipt of a request from a State for technical assistance with respect to determining whether a State plan or State child health plan may provide medical assistance for a specific test for the early detection of preeclampsia, including a biomarker test described in subsection (c), provide such technical assistance to such State. (2) Rule of construction Nothing in this subsection shall be construed as creating a requirement for a State to request or receive the technical assistance described in paragraph (1) as a condition of providing medical assistance for a specific test for the early detection of preeclampsia, or of receiving Federal financial participation for such medical assistance. (c) Biomarker tests To be considered For purposes of this section, the Secretary shall consider advanced biomarker tests for the early detection of preeclampsia, including any such test that is regulated and cleared under the Federal Food, Drug, and Cosmetic Act as a device (as defined in section 201(h) of such Act), and any such laboratory-developed testing service furnished by a clinical laboratory that is certified under section 353 of the Public Health Service Act to perform high-complexity testing..